Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease

OBJECTIVE—The aim of this study was to find an effective treatment for the genetic form of diabetes that is present in some Huntington's disease patients and in Huntington's disease mouse models. Huntington's disease is a neurodegenerative disorder caused by a polyglutamine expansion within the huntingtin protein. Huntington's disease patients exhibit neuronal dysfunction/degeneration, chorea, and progressive weight loss. Additionally, they suffer from abnormalities in energy metabolism affecting both the brain and periphery. Similarly to Huntington's disease patients, mice expressing the mutated human huntingtin protein also exhibit neurodegenerative changes, motor dysfunction, perturbed energy metabolism, and elevated blood glucose levels. RESEARCH DESIGN AND METHODS—Huntington's disease mice were treated with an FDA-approved antidiabetic glucagon-like peptide 1 receptor agonist, exendin-4 (Ex-4), to test whether euglycemia could be achieved, whether pancreatic dysfunction could be alleviated, and whether the mice showed any neurological benefit. Blood glucose and insulin levels and various appetite hormone concentrations were measured during the study. Additionally, motor performance and life span were quantified and mutant huntingtin (mhtt) aggregates were measured in both the pancreas and brain. RESULTS—Ex-4 treatment ameliorated abnormalities in peripheral glucose regulation and suppressed cellular pathology in both brain and pancreas in a mouse model of Huntington's disease. The treatment also improved motor function and extended the survival time of the Huntington's disease mice. These clinical improvements were correlated with reduced accumulation of mhtt protein aggregates in both islet and brain cells. CONCLUSIONS—Targeting both peripheral and neuronal deficits, Ex-4 is an attractive agent for therapeutic intervention in Huntington's disease patients suffering from diabetes.

[1]  Å. Lindström,et al.  Ornithology: Arctic waders are not capital breeders , 2001, Nature.

[2]  S. W. Davies,et al.  Formation of polyglutamine inclusions in non-CNS tissue. , 1999, Human molecular genetics.

[3]  J. Egan,et al.  Mechanisms of action of glucagon-like peptide 1 in the pancreas. , 2007, Pharmacology & therapeutics.

[4]  L. Rossetti,et al.  Hypothalamic insulin signaling is required for inhibition of glucose production , 2002, Nature Medicine.

[5]  N. Bukan,et al.  Decreased plasma adiponectin is associated with insulin resistance and HDL cholesterol in overweight subjects. , 2007, Endocrine journal.

[6]  J. Egan,et al.  The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes. , 2002, The Journal of clinical endocrinology and metabolism.

[7]  T. Vilsbøll,et al.  Liraglutide, a once‐daily human GLP‐1 analogue, improves pancreatic B‐cell function and arginine‐stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[8]  R. Hichwa,et al.  PET scan investigations of Huntington's disease: Cerebral metabolic correlates of neurological features and functional decline , 1986, Annals of neurology.

[9]  Karen Marder,et al.  Energy balance in early-stage Huntington disease. , 2005, The American journal of clinical nutrition.

[10]  J. Cooper,et al.  Mitochondrial defect in Huntington's disease caudate nucleus , 1996, Annals of neurology.

[11]  N. Greig,et al.  Effects of 3 months of continuous subcutaneous administration of glucagon-like peptide 1 in elderly patients with type 2 diabetes. , 2003, Diabetes care.

[12]  M. Bothwell,et al.  Functional interactions of neurotrophins and neurotrophin receptors. , 1995, Annual review of neuroscience.

[13]  A. Morton,et al.  Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington’s disease is not improved by treatment with hypoglycaemic agents , 2005, Experimental Brain Research.

[14]  T. Videen,et al.  Selective defect of in vivo glycolysis in early Huntington's disease striatum , 2007, Proceedings of the National Academy of Sciences.

[15]  M. Hurlbert,et al.  Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. , 1999, Diabetes.

[16]  L. Farrer.  Diabetes mellitus in Huntington disease , 1985, Clinical genetics.

[17]  Dimitri Krainc,et al.  Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration , 2006, Cell.

[18]  H. Herzog,et al.  Striatal glucose consumption in chorea-free subjects at risk of Huntington's disease , 1993, Journal of Neurology.

[19]  W. Banks,et al.  Glucagon-like peptide-1 receptor is involved in learning and neuroprotection , 2003, Nature Medicine.

[20]  P. Brundin,et al.  Effects of α-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionate , 1996, Neuroscience.

[21]  S. D. de Boer,et al.  Hypothalamic, Metabolic, and Behavioral Responses to Pharmacological Inhibition of CNS Melanocortin Signaling in Rats , 2001, The Journal of Neuroscience.

[22]  Zhaohui Feng,et al.  Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats , 2002, Nature Neuroscience.

[23]  P. Brundin,et al.  Effects of alpha-phenyl-tert-butyl nitrone on neuronal survival and motor function following intrastriatal injections of quinolinate or 3-nitropropionic acid. , 1997, Neuroscience.

[24]  O. Andreassen,et al.  Creatine Increases Survival and Delays Motor Symptoms in a Transgenic Animal Model of Huntington's Disease , 2001, Neurobiology of Disease.

[25]  F. Casanueva,et al.  Circulating and cerebrospinal fluid ghrelin and leptin: potential role in altered body weight in Huntington's disease. , 2004, European journal of endocrinology.

[26]  M. White.  Insulin Signaling in Health and Disease , 2003, Science.

[27]  N. Greig,et al.  In vivo biological activity of exendin (1–30) , 2005, Endocrine.

[28]  G. Bates,et al.  Huntingtin aggregation and toxicity in Huntington's disease , 2003, The Lancet.

[29]  F. Anania,et al.  Exendin‐4, a glucagon‐like protein‐1 (GLP‐1) receptor agonist, reverses hepatic steatosis in ob/ob mice , 2006, Hepatology.

[30]  J. Egan,et al.  Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. , 2003, American journal of physiology. Endocrinology and metabolism.

[31]  J. Dunphy,et al.  Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression 1 This work was supported by a grant from the Crohn's and Colitis Foundation of America. 1 , 1998, Molecular and Cellular Endocrinology.

[32]  M. Schwartz,et al.  Intracellular signalling: Key enzyme in leptin-induced anorexia , 2001, Nature.

[33]  D. Manners,et al.  Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy , 2000, Annals of neurology.

[34]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[35]  R. Lefkowitz,et al.  The β2-Adrenergic Receptor Mediates Extracellular Signal-regulated Kinase Activation via Assembly of a Multi-receptor Complex with the Epidermal Growth Factor Receptor* , 2000, The Journal of Biological Chemistry.

[36]  M. Mattson,et al.  Therapeutic perspectives for the treatment of Huntington's disease: treating the whole body. , 2008, Histology and histopathology.

[37]  G. Bates,et al.  Huntingtin and the molecular pathogenesis of Huntington's disease , 2004, EMBO reports.

[38]  A. Kastin,et al.  Entry of exendin-4 into brain is rapid but may be limited at high doses , 2003, International Journal of Obesity.

[39]  J. Egan,et al.  Glucagon-like peptide-1. , 2001, Recent progress in hormone research.

[40]  M. Hayden,et al.  The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease , 1993, Nature Genetics.

[41]  W. Klunk,et al.  Inhibition of Polyglutamine Aggregation in R6/2 HD Brain Slices—Complex Dose–Response Profiles , 2001, Neurobiology of Disease.

[42]  J. Cha,et al.  Transcriptional dysregulation in Huntington’s disease , 2000, Trends in Neurosciences.

[43]  Å. Petersén,et al.  Hypothalamic–endocrine aspects in Huntington's disease , 2006, The European journal of neuroscience.

[44]  D. Borchelt,et al.  Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of huntingtin. , 1999, Human molecular genetics.

[45]  S. Tovar,et al.  Exendin-4 Potently Decreases Ghrelin Levels in Fasting Rats , 2007, Diabetes.

[46]  A. Pocai,et al.  A brain-liver circuit regulates glucose homeostasis. , 2005, Cell metabolism.

[47]  Rudolf Krska,et al.  Mycotoxin analysis: An update , 2008, Food additives & contaminants. Part A, Chemistry, analysis, control, exposure & risk assessment.

[48]  O. Andreassen,et al.  Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. , 2001, Neurobiology of disease.

[49]  Erik Renström,et al.  The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. , 2005, Human molecular genetics.

[50]  Raeann L. Carrier,et al.  Metformin therapy in a transgenic mouse model of Huntington's disease , 2007, Neuroscience Letters.

[51]  R. Lefkowitz,et al.  The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. , 2000, The Journal of biological chemistry.

[52]  N. Aziz,et al.  Hypothalamic Dysfunction and Neuroendocrine and Metabolic Alterations in Huntington Disease: Clinical Consequences and Therapeutic Implications , 2007, Reviews in the neurosciences.

[53]  N. Greig,et al.  Evidence of GLP-1-mediated neuroprotection in an animal model of pyridoxine-induced peripheral sensory neuropathy , 2007, Experimental Neurology.

[54]  P. MacDonald,et al.  Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. , 1999, Diabetes.

[55]  G. Bertilsson,et al.  Peptide hormone exendin‐4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of parkinson's disease , 2008, Journal of neuroscience research.